PF-06447475 is primarily investigated for its potential therapeutic applications in the treatment of neurodegenerative diseases, particularly Parkinson's disease. It functions as a potent and selective inhibitor of LRRK2 kinase, a protein implicated in the pathogenesis of familial and sporadic forms of Parkinson's. By targeting LRRK2, this compound aims to reduce neuroinflammation and neuronal cell death, which are critical factors in disease progression. Its application in preclinical studies has shown promise in improving motor function and slowing disease-related neurodegeneration. Researchers are exploring its efficacy and safety profile to determine its suitability for clinical use, potentially offering a novel approach to managing Parkinson's disease and related conditions.